We report a case of a 68-year-old man diagnosed with pulmonary pleomorphic 
carcinoma who showed partial response after a single treatment with camrelizumab 
(PD1 monoclonal antibody). The patient's tumor was positive for programmed cell 
death ligand 1 (PD-L1) and progressed rapidly after a course of chemotherapy. 
Fortunately, the tumors dramatically shrank after one cycle of camrelizumab, an 
anti-programmed cell death-1 (PD-1) antibody developed by Chinese Hengrui 
Medicine. In conclusion, camrelizumab may be a good treatment option, especially 
in tumors that express PD-L1.